Eli Lilly & Co. has updated the U.S. warning labels on Zyprexa and
Symbyax to include new warnings for weight gain and hyperlipidemia
and updated information in the label for hyperglycemia. (WSJ)
Powered by LSoft's LISTSERV(R) list management software